Investors looking for sources of passive income to fuel their retirement dreams face a dilemma. Lately, Pfizer (NYSE: PFE) ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

We recently published a list of Jim Cramer Recently Discussed These 15 Stocks. In this article, we are going to take a look ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

The updated warnings highlight a rare risk of heart inflammation in teen boys and young men, CBS News reported. The warning ...

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...